ELITE II and Val-HeFT are different trials: together what do they tell us?
<p>Abstract</p> <p>The Losartan Heart Failure Survival Study (ELITE II) and the Valsartan Heart Failure Trial (Val-HeFT) both evaluated the efficacy and tolerability of a selective angiotensin II receptor antagonist on morbidity and mortality in patients with symptomatic heart fail...
Main Author: | Dickstein Kenneth |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2001-09-01
|
Series: | Current Controlled Trials in Cardiovascular Medicine |
Subjects: | |
Online Access: | http://cvm.controlled-trials.com/content/2/5/240 |
Similar Items
-
Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT?
by: John JV McMurray
Published: (2001-06-01) -
Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock
by: Rinaldo Bellomo, et al.
Published: (2020-02-01) -
In Vitro Studies of Fermented Korean Chung-Yang Hot Pepper Phenolics as Inhibitors of Key Enzymes Relevant to Hypertension and Diabetes
by: Su-Jung Yeon, et al.
Published: (2019-10-01) -
Renin Angiotensin System (RAS) Pathways in COVID Pathogenesis
by: Sampreeti Mukherjee, et al.
Published: (2023-01-01) -
Treatment and Management of Hypertension by Targeting ACE Inhibitors: in silico Approach
by: Seema Bawa, et al.
Published: (2019-03-01)